51
|
Chen T, Huang Z, Tian Y, Lin B, He R, Wang H, Ouyang P, Chen H, Wu L. Clinical significance and prognostic value of Triosephosphate isomerase expression in gastric cancer. Medicine (Baltimore) 2017; 96:e6865. [PMID: 28489783 PMCID: PMC5428617 DOI: 10.1097/md.0000000000006865] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Triosephosphate isomerase (TPI) is highly expressed in many human cancers and is involved in migration and invasion of cancer cells. However, TPI clinicopathological significance and prognostic value in gastric cancer (GC) are not yet well defined. The aim of the present work was to evaluate TPI expression in GC tissue and its prognostic value in GC patients.TPI expression was analyzed in 92 primary GC tissues and 80 adjacent normal mucosa tissues from GC patients undergoing gastrectomy by immunohistochemical analysis of tissue microarrays (TMAs). Univariate and multivariate analyses were performed to investigate TPI prognostic significance in GC patients.Immunohistochemical staining score showed that TPI expression in cancer tissues was significantly higher than in adjacent normal mucosa (P < .001). Univariate analysis revealed that TPI expression, depth of invasion, lympho node metastasis, tumor node metastasis (TNM) stage, and tumor diameter were associated with negative prognostic predictors for overall survival in GC patients (P < .05). High TPI expression represented a significant predictor of shorter survival in GC patients with positive lymphatic metastasis (P = .022) and tumor diameter >5 cm (P = .018). Cox multivariate analysis identified TPI expression, TNM stage, and tumor diameter as independent prognostic factors in GC patients.TPI expression might be considered as a novel prognostic factor to evaluate GC patients' survival.
Collapse
Affiliation(s)
- Tingting Chen
- Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, Guangdong
| | - Zhigang Huang
- Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, Guangdong
- Dongguan Key Laboratory of Environmental Medicine, Guangdong
| | - Yunxiao Tian
- Department of Pathology, Handan Central Hospital, Hebei
| | - Bode Lin
- Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, Guangdong
| | - Rongwei He
- Department of Epidemiology and Health Statistics, School of Public Health, Guangdong Medical University, Guangdong
| | - Haiwei Wang
- Department of Pathology, Handan Central Hospital, Hebei
| | - Ping Ouyang
- Scientific Research Centre, Guangdong Medical University, Guangdong
| | - Haoqin Chen
- Department of Internal Medicine, Dalang Hospital of Dongguan City, Guangdong, China
| | - Lili Wu
- Department of Internal Medicine, Dalang Hospital of Dongguan City, Guangdong, China
| |
Collapse
|
52
|
Mei Y, Yang JP, Qian CN. For robust big data analyses: a collection of 150 important pro-metastatic genes. CHINESE JOURNAL OF CANCER 2017; 36:16. [PMID: 28109319 PMCID: PMC5251273 DOI: 10.1186/s40880-016-0178-z] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/19/2016] [Accepted: 11/03/2016] [Indexed: 02/08/2023]
Abstract
Metastasis is the greatest contributor to cancer-related death. In the era of precision medicine, it is essential to predict and to prevent the spread of cancer cells to significantly improve patient survival. Thanks to the application of a variety of high-throughput technologies, accumulating big data enables researchers and clinicians to identify aggressive tumors as well as patients with a high risk of cancer metastasis. However, there have been few large-scale gene collection studies to enable metastasis-related analyses. In the last several years, emerging efforts have identified pro-metastatic genes in a variety of cancers, providing us the ability to generate a pro-metastatic gene cluster for big data analyses. We carefully selected 285 genes with in vivo evidence of promoting metastasis reported in the literature. These genes have been investigated in different tumor types. We used two datasets downloaded from The Cancer Genome Atlas database, specifically, datasets of clear cell renal cell carcinoma and hepatocellular carcinoma, for validation tests, and excluded any genes for which elevated expression level correlated with longer overall survival in any of the datasets. Ultimately, 150 pro-metastatic genes remained in our analyses. We believe this collection of pro-metastatic genes will be helpful for big data analyses, and eventually will accelerate anti-metastasis research and clinical intervention.
Collapse
Affiliation(s)
- Yan Mei
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
| | - Jun-Ping Yang
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China
| | - Chao-Nan Qian
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China. .,Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, Guangzhou, 510060, Guangdong, P. R. China.
| |
Collapse
|
53
|
Chen D, Dang BL, Huang JZ, Chen M, Wu D, Xu ML, Li R, Yan GR. MiR-373 drives the epithelial-to-mesenchymal transition and metastasis via the miR-373-TXNIP-HIF1α-TWIST signaling axis in breast cancer. Oncotarget 2016. [PMID: 26196741 PMCID: PMC4741723 DOI: 10.18632/oncotarget.4702] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Our previous proteomics study revealed that thioredoxin-interacting protein (TXNIP) was down-regulated by miR-373. However, little is known of the mechanism by which miR-373 decreases TXNIP to stimulate metastasis. In this study, we show that miR-373 promotes the epithelial-to-mesenchymal transition (EMT) in breast cancer. MiR-373 suppresses TXNIP by binding to the 3'UTR of TXNIP, which in turn, induces cancer cell EMT and metastasis. TXNIP co-expression, but not the TXNIP-3'UTR, reverses the enhancement of EMT, migration, invasion and metastasis induced by miR-373. MiR-373 stimulates EMT, migration and invasion through TXNIP-dependent reactive oxygen species (ROS) reduction. Mechanistically, miR-373 up-regulates and activates the HIF1α-TWIST signaling axis via the TXNIP pathway. Consequently, TWIST induces miR-373 expression by binding to the promoter of the miR-371-373 cluster. Clinically, miR-373 is negatively associated with TXNIP and positively associated with HIF1α and TWIST, and activation of the miR-373-TXNIP-HIF1α-TWIST signaling axis is correlated with a worse outcome in patients with breast cancer. This signaling axis may be an independent prognostic factor for patients with breast cancer.
Collapse
Affiliation(s)
- D Chen
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China.,Key Laboratory for Major Obstetric Diseases of Guangdong Province and Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Bian-Li Dang
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
| | - Jin-zhou Huang
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
| | - Min Chen
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
| | - Di Wu
- Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Man-Li Xu
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
| | - Rong Li
- Cancer Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Guang-Rong Yan
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China.,Institutes of Life and Health Engineering, Jinan University, Guangzhou, China.,Key Laboratory for Major Obstetric Diseases of Guangdong Province and Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| |
Collapse
|
54
|
Vázquez-Arreguín K, Tantin D. The Oct1 transcription factor and epithelial malignancies: Old protein learns new tricks. BIOCHIMICA ET BIOPHYSICA ACTA 2016; 1859:792-804. [PMID: 26877236 PMCID: PMC4880489 DOI: 10.1016/j.bbagrm.2016.02.007] [Citation(s) in RCA: 57] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/12/2015] [Revised: 02/06/2016] [Accepted: 02/09/2016] [Indexed: 01/29/2023]
Abstract
The metazoan-specific POU domain transcription factor family comprises activities underpinning developmental processes such as embryonic pluripotency and neuronal specification. Some POU family proteins efficiently bind an 8-bp DNA element known as the octamer motif. These proteins are known as Oct transcription factors. Oct1/POU2F1 is the only widely expressed POU factor. Unlike other POU factors it controls no specific developmental or organ system. Oct1 was originally described to operate at target genes associated with proliferation and immune modulation, but more recent results additionally identify targets associated with oxidative and cytotoxic stress resistance, metabolic regulation, stem cell function and other unexpected processes. Oct1 is pro-oncogenic in multiple contexts, and several recent reports provide broad evidence that Oct1 has prognostic and therapeutic value in multiple epithelial tumor settings. This review focuses on established and emerging roles of Oct1 in epithelial tumors, with an emphasis on mechanisms of transcription regulation by Oct1 that may underpin these findings. This article is part of a Special Issue entitled: The Oct Transcription Factor Family, edited by Dr. Dean Tantin.
Collapse
Affiliation(s)
- Karina Vázquez-Arreguín
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84112, USA
| | - Dean Tantin
- Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84112, USA.
| |
Collapse
|
55
|
Zhai JS, Song JG, Zhu CH, Wu K, Yao Y, Li N. Expression of APPL1 is correlated with clinicopathologic characteristics and poor prognosis in patients with gastric cancer. ACTA ACUST UNITED AC 2016; 23:e95-e101. [PMID: 27122990 DOI: 10.3747/co.23.2775] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
BACKGROUND Although appl1 is overexpressed in many cancers, its status in gastric cancer (gc) is not known. In the present study, we used relevant pathologic and clinical data to investigate appl1 expression in patients with gc. METHODS In 47 gc and 27 non-gc surgical specimens, immunohistochemistry was used to detect the expression of appl1, and reverse-transcriptase polymerase chain reaction (rt-pcr) was used to detect messenger rna (mrna). A scatterplot visualized the relationship between survival time and mrna expression in gc patients. The log-rank test and other survival statistics were used to determine the association of appl1 expression with the pathologic features of the cancer and clinical outcomes. RESULTS In gc, appl1 was expressed in 28 of 47 specimens (59.6%), and in non-gc, it was expressed in 7 of 23 specimens (30.4%, p < 0.05). The expression of mrna in gc was 0.82 [95% confidence interval (ci): 0.78 to 0.86], and in non-gc, it was 0.73 (95% ci: 0.69 to 0.77; p < 0.05). Immunohistochemistry demonstrated that, in gc, appl1 expression was correlated with depth of infiltration (p = 0.005), lymph node metastasis (p = 0.017), and TNM stage (p = 0.022), but not with pathologic type (p = 0.41). Testing by rt-pcr demonstrated that, in gc, appl1 mrna expression was correlated with depth of infiltration (p = 0.042), lymph node metastasis (p = 0.031), and TNM stage (p = 0.04), but again, not with pathologic type (p = 0.98). The correlation coefficient between survival time and mrna expression was -0.83 (p < 0.01). Overexpression of appl1 protein (hazard ratio: 3.88; 95% ci: 1.07 to 14.09) and mrna (hazard ratio: 4.23; 95% ci: 3.09 to 15.11) was a risk factor for death in patients with gc. CONCLUSIONS Expression of appl1 is increased in gc. Overexpression is prognostic for a lethal outcome.
Collapse
Affiliation(s)
- J S Zhai
- Postgraduate Team, Chinese pla General Hospital, Medical School of Chinese pla, Beijing, P.R.C.;; Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| | - J G Song
- Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| | - C H Zhu
- Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| | - K Wu
- Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| | - Y Yao
- Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| | - N Li
- Postgraduate Team, Chinese pla General Hospital, Medical School of Chinese pla, Beijing, P.R.C.;; Department of Gastroenterology, Chinese pla 309 Hospital, Beijing, P.R.C
| |
Collapse
|
56
|
Huang JZ, Chen M, Zeng M, Xu SH, Zou FY, Chen D, Yan GR. Down-regulation of TRPS1 stimulates epithelial-mesenchymal transition and metastasis through repression ofFOXA1. J Pathol 2016; 239:186-96. [PMID: 26969828 DOI: 10.1002/path.4716] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2015] [Revised: 02/02/2016] [Accepted: 02/20/2016] [Indexed: 02/06/2023]
Affiliation(s)
- Jin-Zhou Huang
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
| | - Min Chen
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
| | - Ming Zeng
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
| | - Song-Hui Xu
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
| | - Fei-Yan Zou
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
| | - De Chen
- Biomedicine Research Centre and Department of Surgery; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
- Key Laboratory for Major Obstetric Diseases of Guangdong Province; Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes; Guangzhou People's Republic of China
| | - Guang-Rong Yan
- Institutes of Life and Health Engineering, Jinan University; and Biomedicine Research Centre; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
- Biomedicine Research Centre and Department of Surgery; Third Affiliated Hospital of Guangzhou Medical University; People's Republic of China
- Key Laboratory for Major Obstetric Diseases of Guangdong Province; Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes; Guangzhou People's Republic of China
| |
Collapse
|
57
|
Wen L, Liang C, Chen E, Chen W, Liang F, Zhi X, Wei T, Xue F, Li G, Yang Q, Gong W, Feng X, Bai X, Liang T. Regulation of Multi-drug Resistance in hepatocellular carcinoma cells is TRPC6/Calcium Dependent. Sci Rep 2016; 6:23269. [PMID: 27011063 PMCID: PMC4806320 DOI: 10.1038/srep23269] [Citation(s) in RCA: 75] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2015] [Accepted: 03/03/2016] [Indexed: 12/19/2022] Open
Abstract
Hepatocellular carcinoma (HCC) is notoriously refractory to chemotherapy because of its tendency to develop multi-drug resistance (MDR), whose various underlying mechanisms make it difficult to target. The calcium signalling pathway is associated with many cellular biological activities, and is also a critical player in cancer. However, its role in modulating tumour MDR remains unclear. In this study, stimulation by doxorubicin, hypoxia and ionizing radiation was used to induce MDR in HCC cells. A sustained aggregation of intracellular calcium was observed upon these stimuli, while inhibition of calcium signalling enhanced the cells' sensitivity to various drugs by attenuating epithelial-mesenchymal transition (EMT), Hif1-α signalling and DNA damage repair. The effect of calcium signalling is mediated via transient receptor potential canonical 6 (TRPC6), a subtype of calcium-permeable channel. An in vivo xenograft model of HCC further confirmed that inhibiting TRPC6 enhanced the efficacy of doxorubicin. In addition, we deduced that STAT3 activation is a downstream signalling pathway in MDR. Collectively, this study demonstrated that the various mechanisms regulating MDR in HCC cells are calcium dependent through the TRPC6/calcium/STAT3 pathway. We propose that targeting TRPC6 in HCC may be a novel antineoplastic strategy, especially combined with chemotherapy.
Collapse
Affiliation(s)
- Liang Wen
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Chao Liang
- Department of General Surgery, Ningbo Medical Treatment Center Lihuili Hospital, Ningbo, PR China
| | - Enjiang Chen
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Wei Chen
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Feng Liang
- Department of Neurosurgery Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Xiao Zhi
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Tao Wei
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Fei Xue
- Department of Hepatobiliary and Pancreatic Surgery, Henan Province People's Hospital, Henan, PR China
| | - Guogang Li
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Qi Yang
- Center for Immunology and Microbial Disease,Albany Medical College, ME-205 47 New Scotland Ave., MC-151, Albany, New York, USA
| | - Weihua Gong
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Xinhua Feng
- Life Sciences Institute and Innovation Center for Cell Signaling Network, Zhejiang University, Hangzhou, PR China
| | - Xueli Bai
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China
| | - Tingbo Liang
- Department of General Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, PR China.,Collaborative Innovation Center for Cancer Medicine, Zhejiang University, Hangzhou, PR China
| |
Collapse
|
58
|
Hao G, Zheng J, Huo R, Li J, Wen K, Zhang Y, Liang G. Smilax glabra Roxb targets Aktp-Thr308 and inhibits Akt-mediated signaling pathways in SGC7901 cells. J Drug Target 2015; 24:557-65. [PMID: 26607178 DOI: 10.3109/1061186x.2015.1113540] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Guangzhi Hao
- Department of Neurosurgery, The Graduate Training Base of General Hospital of Shenyang Military Area Command, Liaoning Medical College, Shenyang, Liaoning, China
| | - Jun Zheng
- Department of Outpatient, The 463rd Hospital of PLA, Shenyang, Liaoning, China, and
| | - Rentao Huo
- Department of Neurosurgery, The Graduate Training Base of General Hospital of Shenyang Military Area Command, Liaoning Medical College, Shenyang, Liaoning, China
| | - Jingchen Li
- Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning, China
| | - Kai Wen
- Department of Neurosurgery, The Graduate Training Base of General Hospital of Shenyang Military Area Command, Liaoning Medical College, Shenyang, Liaoning, China
| | - Yinsong Zhang
- Department of Neurosurgery, The Graduate Training Base of General Hospital of Shenyang Military Area Command, Liaoning Medical College, Shenyang, Liaoning, China
| | - Guobiao Liang
- Department of Neurosurgery, General Hospital of Shenyang Military Area Command, Shenyang, Liaoning, China
| |
Collapse
|
59
|
Ding W, Fan XL, Xu X, Huang JZ, Xu SH, Geng Q, Li R, Chen D, Yan GR. Epigenetic silencing of ITGA2 by MiR-373 promotes cell migration in breast cancer. PLoS One 2015; 10:e0135128. [PMID: 26258411 PMCID: PMC4530956 DOI: 10.1371/journal.pone.0135128] [Citation(s) in RCA: 45] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2015] [Accepted: 07/18/2015] [Indexed: 12/19/2022] Open
Abstract
The loss of ITGA2 plays an important role in cancer metastasis in several solid cancers. However, the molecular mechanism of ITGA2 loss in primary cancers remains unclear. In this study, we found that a lower ITGA2 protein level was observed in breast cancers compared to adjacent non-cancerous breast tissues. Interestingly, the reduction degree of ITGA2 at the protein level was far more than that at the mRNA level. We further showed that the translation of ITGA2 mRNA was directly inhibited by miR-373 through binding to ITGA2-3’UTR. Silencing of ITGA2 detached cell-cell interactions, induced the deploymerization of stress fiber F-actin and stimulated cancer cell migration, similar to the effect of miR-373 over-expression. The co-expression of ITGA2, not ITGA2-3’UTR, could abrogate miR-373-induced cancer cell migration because that the expression of ITGA2-3’UTR was inhibited by co-transfected miR-373. ITGA2 protein level was inversely associated with miR-373 level in breast cancers (r = -0.663, P<0.001). 73.33% of breast cancer patients with high miR-373 and low ITGA2 expression exhibited the lymph node-positive metastases. Together, our results show that epigenetic silencing of ITGA2 by miR-373 stimulates breast cancer migration, and miR-373high/ITGA2low may be as a prognosis biomarker for breast cancer patients.
Collapse
Affiliation(s)
- Wen Ding
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Xiao-Lu Fan
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Xuan Xu
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Jin-Zhou Huang
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Song-Hui Xu
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
| | - Qian Geng
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Rong Li
- Department of Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, China
- * E-mail: (G-RY); (DC); (RL)
| | - De Chen
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
- Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Guangzhou, China
- * E-mail: (G-RY); (DC); (RL)
| | - Guang-Rong Yan
- Institutes of Life and Health Engineering, Jinan University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
- Biomedicine Research Center and Department of Surgery, The Third Affiliated Hospital of Guangzhou Medicine University, Guangzhou, China
- Key Laboratory for Major Obstetric Diseases of Guangdong Province, Key Laboratory of Reproduction and Genetics of Guangdong Higher Education Institutes, Guangzhou, China
- * E-mail: (G-RY); (DC); (RL)
| |
Collapse
|